The association of Raynaud's syndrome with cisplatin-based chemotherapy — A meta-analysis

  • Melvin Mohokum
    Correspondence
    Corresponding author at: Charité Universitätsmedizin Berlin, Department of Biometry and Clinical Epidemiology, Campus Charité Mitte, Bettenhochhaus 12. Ebene, Charitéplatz 1, 10098 Berlin, Germany. Tel.: +49 30 70550709, +49 176 61063647(mobile); fax: +49 30 70550716.
    Affiliations
    Department of Biometry and Clinical Epidemiology, Charité Universitätsmedizin Berlin, Berlin, Germany
    Search for articles by this author
  • Peter Hartmann
    Affiliations
    Department of Biometry and Clinical Epidemiology, Charité Universitätsmedizin Berlin, Berlin, Germany
    Search for articles by this author
  • Peter Schlattmann
    Affiliations
    Department of Medical Statistics, Computer Sciences and Documentation, University Hospital of Friedrich-Schiller University Jena, Jena, Germany
    Search for articles by this author
Published:April 23, 2012DOI:https://doi.org/10.1016/j.ejim.2012.03.016

      Abstract

      Background

      Vasospastic disorders of the digital circulation such as the Raynaud's syndrome (RS) are known side-effects of treatment of cisplatin-based chemotherapy. The prevalence of RS in patients during treatment with cisplatin-based chemotherapy is not well-defined.

      Objective

      The objective of this paper was to assess the prevalence of RS in patients receiving cisplatin-based chemotherapy — a meta-analysis of published data was performed.

      Material and methods

      The PubMed database of the National Library of Medicine and ISI Web of Knowledge was used for studies dealing with RS and patients receiving cisplatin-based chemotherapy. The studies provided sufficient data to estimate the prevalence of RS in patients receiving cisplatin-based chemotherapy. A forest plot was determined by the revealed prevalences. Statistical analysis was based on methods for a random effects meta-analysis and a finite mixture model for proportions. Publication bias was investigated with the linear regression test (Egger's method). A meta-regression was conducted by the year of publication and latitude.

      Results

      24 eligible studies, contributing data on 2749 subjects, were included in this meta-analysis. For RS in patients receiving cisplatin-based chemotherapy a pooled prevalence of 24% and 95% CI (0.175, 0.313) was obtained. A mixture model analysis found four latent classes. Statistically, publication bias was not present (p-value 0.74). The meta-regression indicated that the odds ratio increased when the latitude increased, too (p-value 0.011).

      Conclusion

      Despite some heterogeneity there is a possible indication of an association between RS and patients receiving cisplatin-based chemotherapy.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Block J.A.
        • Sequeira W.
        Raynaud's phenomenon.
        Lancet. 2001; 357: 2042-2048
        • Heidrich H.
        Functional vascular diseases: Raynaud's syndrome, acrocyanosis and erythromelalgia.
        Vasa. 2010; 39: 33-41
        • Fraenkel L.
        Raynaud's phenomenon: epidemiology and risk factors.
        Curr Rheumatol Rep. 2002; 4: 123-128
        • Doll D.C.
        • Yarbro J.W.
        Vascular toxicity associated with antineoplastic agents.
        Semin Oncol. 1992; 19: 580-596
        • Hansen S.W.
        • Olsen N.
        Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold.
        J Clin Oncol. 1989; 7: 940-942
        • Vogelzang N.J.
        • Torkelson J.L.
        • Kennedy B.J.
        Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin.
        Cancer. 1985; 56: 2765-2770
        • Rozencweig M.
        • von Hoff D.D.
        • Slavik M.
        • Muggia F.M.
        Cis-diamminedichloroplatinum (II). A new anticancer drug.
        Ann Intern Med. 1977; 86: 803-812
        • Heier M.S.
        • Nilsen T.
        • Graver V.
        • Aass N.
        • Fossa S.D.
        Raynaud's phenomenon after combination chemotherapy of testicular cancer, measured by laser Doppler flowmetry. A pilot study.
        Br J Cancer. 1991; 63: 550-552
        • Bosl G.J.
        • Geller N.L.
        • Bajorin D.
        • et al.
        A randomized trial of etoposide+cisplatin versus vinblastine+bleomycin+cisplatin+cyclophosphamide+dactinomycin in patients with good-prognosis germ cell tumors.
        J Clin Oncol. 1988; 6: 1231-1238
        • de Wit R.
        • Stoter G.
        • Kaye S.B.
        • et al.
        Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
        J Clin Oncol. 1997; 15: 1837-1843
        • Eeles R.
        • Tait D.M.
        • Peckham M.J.
        Lhermitte's sign as a complication of cisplatin-containing chemotherapy for testicular cancer.
        Cancer Treat Rep. 1986; 70: 905-907
      1. Schwarzer G. meta: Meta-Analysis with R. In. 1.5-0 ed; 2010: Fixed and random effects meta-analysis. Functions for tests of bias, forest and funnel plot.

        • Higgins J.P.
        • Thompson S.G.
        Quantifying heterogeneity in a meta-analysis.
        Stat Med. 2002; 21: 1539-1558
        • Higgins J.P.
        • Thompson S.G.
        • Deeks J.J.
        • Altman D.G.
        Measuring inconsistency in meta-analyses.
        BMJ. 2003; 327: 557-560
        • DerSimonian R.
        • Laird N.
        Meta-analysis in clinical trials.
        Control Clin Trials. 1986; 7: 177-188
        • Schlattmann P.
        Medical applications of finite mixture models.
        Springer-Verlag, Berlin Heidelberg2009
        • Galbraith R.F.
        Graphical display of estimates having differing standard errors.
        Technometrics. 1988; 30: 271-281
        • Egger M.
        • Davey Smith G.
        • Schneider M.
        • Minder C.
        Bias in meta-analysis detected by a simple, graphical test.
        BMJ. 1997; 315: 629-634
        • Thompson S.G.
        How should meta-regression analyses be undertaken and interpreted.
        Stat Med. 2002; 21: 1559-1573
      2. Lumley T. rmeta: Meta-analysis. In. 2.16 ed; 2009.

      3. Schlattmann P. Finite Mixture Models and metaanalysis tools - based on C.A.MAN. In. 0.64 ed; 2008.

        • Liberati A.
        • Altman D.G.
        • Tetzlaff J.
        • et al.
        The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.
        BMJ. 2009; 339: b2700
        • Weinrich M.C.
        • Maricq H.R.
        • Keil J.E.
        • McGregor A.R.
        • Diat F.
        Prevalence of Raynaud phenomenon in the adult population of South Carolina.
        J Clin Epidemiol. 1990; 43: 1343-1349
        • De Angelis R.
        • Salaffi F.
        • Grassi W.
        Raynaud's phenomenon: prevalence in an Italian population sample.
        Clin Rheumatol. 2006; 25: 506-510
        • Suter L.G.
        • Murabito J.M.
        • Felson D.T.
        • Fraenkel L.
        The incidence and natural history of Raynaud's phenomenon in the community.
        Arthritis Rheum. 2005; 52: 1259-1263
        • Hansen S.W.
        • Olsen N.
        • Rossing N.
        • Rorth M.
        Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin.
        Ann Oncol. 1990; 1: 289-292
        • Vogelzang N.J.
        • Bosl G.J.
        • Johnson K.
        • Kennedy B.J.
        Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer.
        Ann Intern Med. 1981; 95: 288-292
        • Stefenelli T.
        • Kuzmits R.
        • Ulrich W.
        • Glogar D.
        Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer.
        Eur Heart J. 1988; 9: 552-556
        • Pliarchopoulou K.
        • Pectasides D.
        Late complications of chemotherapy in testicular cancer.
        Cancer Treat Rev. 2010; 36: 262-267
        • Chung M.S.
        • Gong H.S.
        • Baek G.H.
        Prevalence of Raynaud's phenomenon in patients with idiopathic carpal tunnel syndrome.
        J Bone Joint Surg Br. 1999; 81: 1017-1019
        • Maricq H.R.
        • Carpentier P.H.
        • Weinrich M.C.
        • et al.
        Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison.
        J Rheumatol. 1997; 24: 879-889
        • Maricq H.R.
        • Carpentier P.H.
        • Weinrich M.C.
        • et al.
        Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France.
        J Rheumatol. 1993; 20: 70-76